Biotechnology Innovation Organization (BIO) has hit out at the US Trade Representative’s (USTR) continued support for a waiver of IP protections for COVID-19 vaccines under the WTO (World Trade Organization) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
The trade group for the US biotech industry has given its reaction to certain elements of the USTR’s 2022 Special 301 Report, including its position on COVID-19 vaccines.
"This proposed agreement would have profound and negative consequences on the USA’s leadership in innovative biotechnology development"A BIO statement speaks of disappointment over science being ‘given away’ in this way.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze